Search Results

publications : AlphaFold3 benchmarking for GPCRs; new structural insights into peptide ligand activation All Don’t Fall Behind—Access the Edge You Need 👉 Access all the news and upcoming events ➤ Already a Premium

When a system approaches full allosteric occupancy, the Schild plot curves and the slope falls below

No one person can be excellent at all of it — and pretending otherwise slows discovery. about trust — the kind of trust built when collaborators confirm your data, replicate your results, and call

Key Questions Answered in this AMA Session How early in vivo models sharpen go/no-go calls.

He argues that early-career researchers often fall into the trap of over-rationalizing too soon—missing

development of cachexia therapeutics Sosei Heptares Webinar Presentation for FY2022 Financial Results Call

Industry News Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May Beat Expectations, EPS Lags “As Precision Medicine is critical, we cannot think about one size fits all

The donors used in this technique have longer half-lives  than other fluorophores (between 300μs–1 ms The donors act as light-harvesting antennas, capturing light from all directions, unlike the dipole-dipole

Christopher Prior, as CEO and Reports Recent Drug Discovery Highlights Call for GPCR Papers GPCRs: Signal

Drug pipelines live and die by your ability to make fast, accurate calls. A renin inhibitor that lowers blood pressure in healthy volunteers might not drop blood pressure at all Reflexes as Drug Design Partners Not all reflexes are enemies. Some can make a mediocre drug shine.

collaborations GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple Myeloma Call

A compound shows no response in one assay, and we call it “selective.”

interactions of the serotonin1A receptor Industry News Neurocrine Biosciences Announces Conference Call

GPCR Ecosystem this fall.

Artificial Intelligence for Drug Discovery Call for GPCR Papers GPCRs: Signal Transduction.

announce that we've been working tirelessly to bring you a simple, beautiful, and insightful collection of all This is your last call before the curtain drops: Classified GPCR News is going VIP-only next year! That's right, all the tidbits below will be for Premium Members ' eyes only.

Listing Rule 5635(c)(4) arcoscreen is one of the 13 biotech companies to discover in western in 2023 Call

With just one week left, becoming a premium member is all it takes to benefit from this discount! Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Call

You can find all the necessary information on the Logo Contest page. to Vertex for $48 million Merck KGgA collaborates with Exscientia plc in deal worth up to $674M 2023 Half-Year

Call for GPCR Papers GPCRs: Signal Transduction. Ends tomorrow - March 31st, 2023.

All information is available on the Logo Contest page. Program Receives €4 Million Grant Confo Therapeutics Appoints Stephen Dowd As Chief Business Officer Call

By increasing sensitivity, so-called “silent” antagonists reveal themselves as weak agonists.

Targeted and Immuno-oncology Sosei Heptares Adds World-leading Expertise to its Scientific Advisory Board Call

) Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Call

Gregory Tall and team's study on GPR114/ADGRG5, activated by tethered-peptide-agonist, a cleaved adhesion substance use disorders Industry News Crinetics’ Once-Daily Oral Paltusotine Achieved The Primary And All Stephen Dowd As Chief Business Officer Septerna Announces Novel GPCR-targeted Program Acquired by Vertex Call

Global Healthcare Conference CEO Raymond Stevens to Speak at STAT Future Summit on Obesity Therapeutics Call

When Two Mechanisms Look the Same Some of the most difficult calls in pharmacology happen when two different

However, over half of non-sensory GPCRs do not have drugs available in the clinic, opening the door to Our portfolio also includes all kinds of dyes, such as pharmacophores conjugated to near-infrared fluorophores Another issue, that is present in all probes but can sometimes be stronger in fluorescent ligands, is Soave M, Briddon SJ, Hill SJ, Stoddart LA.

. 👉 Here’s what the FDA is actually optimizing for, and where most early-stage teams fall short: 1️⃣

Heptares and Neurocrine Biosciences won Top Out-Licensing Deal on the 8th annual Japan Deal of the Year Call